High-sensitivity cardiac troponin (hs-cTn) I or T methods have been in use in certain regions for years but are now increasingly globally adopted, including in the United States. Accordingly, inevitable challenges are created for institutions transitioning from conventional cardiac troponin (cTn) assays. hs-cTn assays have higher analytic precision at lower concentrations, yielding greater clinical sensitivity for myocardial injury and allowing accurate recognition of small changes in troponin concentration (rise or fall) within a short time frame. Although much of the knowledge regarding troponin biology that was applicable with older troponin assays still holds true, considerable education regarding the differences between conventional cTn and hs-cTn is needed before medical systems convert to the newer methods. This includes a basic understanding of how hs-cTn testing differs from conventional cTn testing and how it is best deployed in different settings, such as the emergency department and inpatient services. This Expert Panel will review important concepts for institutional transition to hs-cTn methodology, providing recommendations useful for education before implementation. (J Am Coll Cardiol 2019;73:1059-77) Siemens, LumiraDx, and Alere; has received grant support from Roche, Abbott Point of Care, and Singulex; has received donation of reagents for research from Roche, Abbott, Siemens, Alere, Singulex, and FABPulous BV; has served on advisory boards for Roche, LumiraDx, FABPulous BV, and Creavo; and as chair of a trial steering committee for a clinical study sponsored by Creavo. Januzzi Jr. et al. J A C C V O L . 7 3 , N O . 9 , 2 0 1 9
A lthough used for many years in several regions, including Europe, Australia, Asia, and Canada, highsensitivity cardiac troponin (hs-cTn) I and T assays have only recently achieved regulatory approval in the United States and are in growing use in other global markets. With transition to more sensitive troponin assays comes the need to develop a consensus regarding aspects that medical systems should consider before implementation of these assays, which differ considerably from "conventional" cardiac troponin (cTn) methods. Additionally, even within the category of hs-cTnI or T assays, there will be variability in cutoff values, sensitivity, and specificity, as well as in the way in which these tests are interpreted.
This document, authored by an Expert
Panel with a broad range of expertise, will provide suggestions to facilitate the transition from conventional cTn to hs-cTn methods, including necessary considerations for laboratory medicine, emergency medicine, cardiology, and those staffing inpatient services. A central theme is the need for collaborative preparation for the transition to hs-cTn methods and the necessity for extensive education. As with other Expert Panels in the Journal, this effort is intended to provide a framework for transition to hs-cTn testing based on the present evidence base; we also provide expert opinion in areas where evidence may be limited, new, and evolving, or where sufficient data to fully inform clinical decision making are lacking.
LABORATORY CONSIDERATIONS
With several hs-cTn assays available at the time of this writing and several others soon to be approved, laboratory medicine specialists should decide which assay meets institutional needs. As well, they represent an important source of education regarding how hs-cTnI or T assays contrast with conventional cTn methods (Online Table 1 ). Some basic education regarding analytic terminology, as illustrated in Figure 1 and explained here, is helpful, because this clarifies how hs-cTn assays perform.
Limit of blank (LoB):
The LoB is considered the background noise present in the analytical measurement system when no troponin is present (1) .
Limit of detection (LoD):
The LoD is the lowest concentration of analyte detectable in 95% of measurements (1) . The imprecision at the LoD is often high, making measurements inaccurate.
Limit of quantitation (LoQ): LoQ is the lowest troponin concentration that can be reported as a number with specified certainty (1), for example, # 20% imprecision.
Coefficient of variation:
A measure of assay imprecision at any given concentration. The coefficient of variation value should be 10% or less at the 99th percentile upper reference limit (URL) for hs-cTn assays. Good precision allows for confident identification of small changes in biomarker concentration (2) . (4, 5) ; accordingly, this URL has been adopted in evidence-based guidelines developed by cardiology (6) and laboratory medicine (7) professional associations and endorsed by the Fourth Universal Definition of Myocardial Infarction Global Task Force (8) . Determination of the 99th percentile URL is far from standardized because of varying criteria for defining a normal population (2) .
Common questions from clinicians regarding hs-cTn methods include the following:
What makes an hs-cTn assay more sensitive? Assays for hs-cTnI or T measurement do not detect a novel troponin isoform. Rather, they enable more sensitive and precise detection at very low troponin concentrations. Although the reagents that have far higher cTn avidity than contemporary assays, which helps optimize signal-to-noise ratio for hs-cTn tests (2) .
How are troponin assays classified as high sensitivity?
To be termed "high sensitivity," it has been proposed that assays allow establishment of sex-specific cutoffs, possess a low LoD, and be capable of measuring values > 50% in both healthy female and male populations with values greater than the LoD. A comparison between hs-cTn and conventional cTn methods is detailed in Online 
CLINICAL CONSIDERATIONS
Before institutional transition to hs-cTn testing, it is important to establish core concepts regarding troponin and how hs-cTn methods differ in terms of deployment and interpretation. The Writing Group If AMI is diagnosed, it can be classified into 1 of 5 different types (Online (12) . For example, for hs-cTnT, a change of 7 ng/l from a baseline of 14 ng/l would be significant (13, 14) . Present data and the Universal Definition of MI (8) suggest that the use of absolute values rather than percentages provides better diagnostic information (13) . We endorse that approach.
Serial testing becomes even more important in patients with chronic comorbid conditions, such as the elderly and those with chronic kidney disease (CKD) (15) for admission level, respectively) (16) . However, no hs-cTnI or T change criteria have perfect sensitivity and specificity for AMI, and thus, clinician judgment remains essential to confirm or refute the diagnosis. In general, with lower change criteria, sensitivity is higher and specificity is lower.
3. The "differential diagnosis" of abnormal hs-cTn is broad at lower concentrations. With higher values, the differential diagnosis narrows (Figure 3 ).
Although a rise or fall in troponin concentration suggests acuity, it is not etiologically specific.
Rising or falling hs-cTn patterns result from a variety of underlying conditions, including pulmonary embolus, myocarditis, or sepsis, as well as AMI. The absolute baseline concentration, as well as the change in hs-cTn, is often one indication of whether an AMI has occurred versus another disease state (17, 18) . For instance, when type 1 MI has occurred, it is common to see rapid and substantial increases in hs-cTn over a few hours (19) . Fewer things mimic such magnitude of increase; however, acute myocarditis can also cause large rises in hs-cTn, with a distribution that overlaps with that for type 1 MI, as can systemic inflammatory response syndromes, such as that associated with sepsis. Chronic cardiac disease and many type 2
MIs will demonstrate both lower baseline hs-cTn concentrations and smaller changes in hs-cTn over the first few hours (20). It is imperative that 0/1h ¼ accelerated diagnostic protocol to rule out MI in patients presenting >3 h from symptoms using a single hs-cTn measurement at presentation, whereas for other patients, an absolute hs-cTn at presentation and 1-h delta are used to rule out or rule in MI or to place patients in an observational zone; 0/2h ¼ accelerated diagnostic protocol that uses maximal levels and absolute delta hs-cTnI or T concentrations at 0 and 2 h to rule out or rule in MI or place patients in an observational zone; 0/3h ¼ accelerated diagnostic protocol that incorporates hs-cTn at 0 and 3 h, hs-cTn change, and time since pain onset to determine which patients are appropriate for discharge or stress testing versus invasive management; GRACE ¼ Global Registry of Acute Coronary Events; High STEACS ¼ High- Sensitivity However, among early presenters (< 2 h from symptom onset), NPV drops to 97.6% (10) . In a recent validation study, the High STEACS pathway excluded MI in 40.7% at presentation and a total of 74.2% at 3 h with 99.5% NPV for 30-day cardiac death or MI (31) .
Use of the GRACE score in combination with the High STEACS pathway was associated with an incremental increase in NPV (99.7%) (10, 31) .
The 0/2h ADP uses maximal levels and absolute delta hs-cTnI or T concentrations at 0 and 2 h to rule out or rule in MI or place patients in an observational zone. In the derivation and validation cohorts, 60% and 78% of patients, respectively, were ruled out, with NPVs for MI approaching 100% (32, 34) .
Compared with ADAPT, the 0/2h algorithm (using either hs-cTnT or I) ruled out 18% to 27% more patients while producing a similar NPV ($ 99%) for MI (35) . In a Canadian cohort (N ¼ 722), the 0/2h hs-cTnT algorithm was 98.7% and 97.6% sensitive to exclude 7-day and 30-day MI, respectively (36) .
The 0/1h ADP rapid rule-out strategy is endorsed as an alternative to the 0/3h algorithm by the 2015 European Society of Cardiology guidelines (37) . With this approach, MI in patients with > 3 h of symptoms can be ruled out using a single hs-cTn measurement at presentation. In other patients, an absolute hs-cTn at presentation and 1-h delta is used to rule out or rule in MI or to place patients in an observational zone.
The approach ruled out 60% of patients with 100% sensitivity and NPV for MI (38) . This was validated in separate cohorts with 99.1% to 100% NPV (37, (39) (40) (41) in studies examining both hs-cTnT and hs-cTnI.
Recent analyses suggest this ADP maintains a high NPV for MI among elderly patients and early presenters (42,43).
Although these studies provide a body of evidence supporting rapid rule-out ADPs, some have questioned their generalizability (44) . Another limitation is that guidelines recommend using these ADPs in conjunction with all available clinical data, such as the patient's ECG and historical data, but no specific guidance is given regarding how to incorporate these data into the algorithm. Finally, studies evaluating the 0/1h and other rapid rule-out algorithms have been largely observational.
An important caveat that is often missed with rapid protocols is that patients who are on the downslope of the time-concentration curve (which often moves more slowly than the upslope) might not manifest a falling pattern over short periods of time. Thus, in patients in whom the index of suspicion is high and the initial values are increased without a clear cause, a later sample can be informative; in some series, up to 26% of patients with AMI may fit into this category (45) .
ADPs INCORPORATING A RISK SCORE/DECISION
AID WITH TROPONIN TESTING. The 0/3h ADP incorporates hs-cTn at 0 and 3 h, hs-cTn change, and time since pain onset (24) to determine which patients are appropriate for discharge or stress testing versus invasive management. In an observational study of 2,727 patients with possible ACS, the 0/3h ADP had an NPV > 99.5% for MI among early (<6 h since pain onset) and late ($6 h) presenters (46, 47) .
Use of the 0/3h ADP was associated with an increase in outpatient management of patients, reduction in stress testing rates, and decreased length of stay compared with usual care with contemporary cTn measures (27) . However, 2 analyses evaluating this algorithm found it might be insufficiently sensitive for MI (30, 31) .
The TIMI risk score for non-ST-segment elevation ACS is frequently used for early risk stratification in the ED (48) . It is insufficiently sensitive to be used alone with a single hs-cTn measurement (49, 50) .
Combining a TIMI score of 0 with hs-cTnT or I less T-MACS also rules in ACS with over 90% positive predictive value (59) . Use of T-MACS increased safe early discharges in a pilot randomized controlled trial (26% vs. 8% for control, p ¼ 0.004) (44) and has been validated with hs-cTnT and cTnI (60) .
The EDACS ADP ( Table 5 ) incorporates a risk score, 0 and 2 h cTn results, and ECG findings. In derivation studies, EDACS classified 42% to 51% of ED patients as low risk for 30-day events, with a sensitivity $99% Radiates to arm or shoulder 5
Pain occurred or worsened with inspiration À4
Pain is reproducible with palpation À6
Total Range À4 to þ28 What is the pre-test probability for MI based on chest pain onset, signs and ECG findings? E.g., typical pain, CPO 2h, ST-segment ↓ (resulting in a PPV for MI ≈ 90%) 1 Does my patient have a readily identifiable non-MI cause for low level cTn elevations? E.g., age, heart failure, aortic stenosis, pulmonary embolism. The more plausible the alternative cause for low level cTn elevations, the less likely that any immediate further diagnostic work-up for MI is justified and/or necessary.
3
What other diagnostic test is useful? 1h/3h cTn re-measurement, echo, stress-echo, CMR, MPI-SPECT.
hs-cTn TESTING AFTER NONCARDIAC SURGERY.
Perioperative cardiovascular events are a major cause of morbidity and mortality among patients undergoing noncardiac surgery (71) . Although conventional cTn assays might not often detect cardiac injury in the post-operative setting, hs-cTn measurement often reveals a surprisingly high incidence of postoperative cardiac injury, and such injury is of prognostic importance. For example, in one study, approximately 35% of patients had post-operative hs-cTnT concentrations above the 99th percentile value of 14 ng/l (72) . Thirty-day mortality for patients with values <14 ng/l was .01% to .05%; with mild elevations (14 to 20 ng/l), it was 1.1%; with values 21 to 64 ng/l, it was 3.0%; for values from 65 to 999 ng/l, it was 9.1%; and for values $1,000 ng/l, it was 29.6%.
The investigators also found the larger the change from baseline, the worse the prognosis (72) . Besides AMI, it is reasonable to assume multiple causes of troponin elevation (such as pulmonary embolism, HF, sepsis) were present: only 7% of patients in this study acknowledged ischemic symptoms, and the ECGs were often not informative (72) . Among those thought to have AMI, most were assumed to be type 2 MIs (73,74); however, it has been noted in small studies that 50% of the events that lead to mortality are plaque rupture events (75) . 
Emergency Department/Hospital Preparation Clinical Laboratory Preparation
Have there been sessions to educate clinicians regarding the transition?
Will an ADP be used in the Emergency Department?
What will the process be for the blood draw in the Emergency Department? Will this occur in Triage or once patient is roomed? Do clinicians understand basic concepts of how high sensitivity troponin differs from previous troponin methods?
Do clinicians understand the distinction between injury and infarction?
Do clinicians understand the differential diagnosis of an abnormal hs-cTn concentration?
Is the Clinical Laboratory ready to provide necessary analytical education?
Has an assay been selected?
Was assay performance acceptable in the local Clinical Laboratory?
Which 99 th percentile cut-off will be used?
Is the Clinical Laboratory able to process samples within a reasonable time-frame? versions. As above, the Writing Group recommends transition to hs-cTn for all hospital services.
For ED-based testing, current evidence supports excluding MI by use of a rapid algorithm (e.g., baseline plus 1-, 2-, or 3-h second sample) for hs-cTn alongside a validated risk score such as EDACS or HEART to identify patients suitable for early discharge. Compared with other rule-out strategies, the serial testing approach for hs-cTn is less likely to miss MI among early presenters and uses a change value that is less susceptible to assay imprecision. For inpatient testing of acute chest discomfort or other signs of myocardial ischemia, it is reasonable to use a 3-h approach, with the recognition that the rapid response for inpatients might run the potential risk of early false negative testing and that at times, there are difficulties in seeing a delayed falling pattern. In contrast to the ED setting, a substantially greater percentage of patients in the hospital setting are likely to have significant, acute comorbid medical conditions that can cause myocardial injury. Thus, clinicians should be mindful of the caveats offered in this document regarding how to approach short-term hs-cTn changes, how to differentiate long-term hs-cTn elevations, the logic regarding coronary versus noncoronary myocardial injury, and distinctions between type 1 and type 2 MI.
Although a common source of interest, information is insufficient regarding use of hs-cTn testing for stable outpatients. In outpatients with chest symptoms, a single outpatient measurement for evaluating chest discomfort is not presently supported; generally, such testing should probably be reserved for the ED environment.
EDUCATION AND IMPLEMENTATION
Given substantial differences between conventional and high-sensitivity assays for troponin measurement, the Writing Group strongly advises against conversion to hs-cTn without a gradual, phased educational process that involves all clinical services affected by this change. This effort should include an assessment of current knowledge, development of strategies for effective knowledge transfer, and ongoing efforts to ensure success (Online Figure 3 ). This approach is critical to avoid confusion, controversy, and potential patient harm. 
